Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
Public ClinicalTrials.gov record NCT05143229. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Trial Of Alpelisib Plus Sacituzumab Govitecan In Patients With Metastatic Or Locally Recurrent HER2-Negative Breast Cancer
Study identification
- NCT ID
- NCT05143229
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- University of Kansas Medical Center
- Other
- Enrollment
- 18 participants
Conditions and interventions
Conditions
Interventions
- Alpelisib Drug
- Sacituzumab govitecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2022
- Primary completion
- Jan 27, 2025
- Completion
- Nov 30, 2026
- Last update posted
- Apr 30, 2026
2022 – 2026
United States locations
- U.S. sites
- 7
- U.S. states
- 2
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Kansas Clinical Research Center | Fairway | Kansas | 66205 | — |
| The University of Kansas Cancer Center - Overland Park | Overland Park | Kansas | 66210 | — |
| The University of Kansas Cancer Center - Indian Creek | Overland Park | Kansas | 66211 | — |
| The University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| The University of Kansas Cancer Center - North Kansas City Hospital | Kansas City | Missouri | 64116 | — |
| The University of Kansas Cancer Center - North | Kansas City | Missouri | 64154 | — |
| The University of Kansas Cancer Center - Lee's Summit | Lee's Summit | Missouri | 64064 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05143229, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05143229 live on ClinicalTrials.gov.